[Elsevier] Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial |
|
This post will be closed automatically in 2026-11-16 09:54
Reward10points
|
10
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trial
10
Utilidad pron車stica de la ecograf赤a a pie de cama previa al alta en pacientes con insuficiencia card赤aca aguda y fracci車n de eyecci車n preservada
10
SSGJ-601 versus Ranibizumab for Macular Edema Secondary to Branch Retinal Vein Occlusion
10
French psychiatric caregivers＊ perceptions of psychedelics: A national survey
20
Posicionamiento SEMERGEN en el manejo del paciente oncol車gico: abordaje integral de la cardiotoxicidad en Atenci車n Primaria
